BioMed Research International

Multiparametric MRI in Prostate Cancer


Status
Published

Lead Editor

1School of Medicine, Koc University, Istanbul, Turkey

2Molecular Imaging Program, NCI, NIH, Bethesda, MD, USA

3Spire Roding Hospital, London, UK

4Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands


Multiparametric MRI in Prostate Cancer

Description

Clinical suspicion of prostate cancer leads us to order transrectal ultrasound- (TRUS-) guided biopsy, which has been the traditional way of obtaining prostate tissue for histopathologic assessment. However, this has a considerable false-negative rate, and tumors may be missed even if they are within the biopsy “template”. This leads to underestimation of the extent of disease.

Prostate cancer imaging landscape has changed substantially in recent years. It is now possible to perform prostate gland magnetic resonance imaging (MRI) using sequences that yield functional information. In addition to morphological T2-weighted sequences, the major functional techniques used for the prostate are diffusion-weighted MRI, dynamic contrast-enhanced MRI, and spectroscopic imaging. These techniques can yield quantitative information that reflects on the biological properties of prostatic tissues. Accurate localization and characterization of prostate cancers via multiparametric prostate MRI (MP-MRI) can be used to direct biopsies and assist in decision-making regarding the use of active treatment or active surveillance in selected patients.

We invite authors to submit original research and review articles that aim to define the evolving role of MP-MRI in prostate cancer detection, risk stratification, and treatment planning. We are interested in articles that will help the clinicians to establish avenues for utilizing MP-MRI in the office in a manner that improves the accuracy of patient counseling in different scenarios such as an elevated PSA without a prior biopsy, elevated PSA and prior negative biopsy, newly diagnosed prostate cancer, and active surveillance. Potential topics include, but are not limited to:

  • Basic interpretation of prostate MRI and factors influencing MRI quality
  • Methods of MRI-targeted biopsy techniques
  • Role of MRI in patients with elevated PSA, previous negative biopsy, low-risk prostate cancer under consideration for surveillance, and intermediate/high-risk disease under consideration for therapy
  • Integration of MRI into the management of men with, or at risk of, prostate cancer
  • Strategies for developing a program in prostate MRI-based detection and therapeutics

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/urology/mmri/ according to the following timetable:

BioMed Research International
 Journal metrics
See full report
Acceptance rate8%
Submission to final decision110 days
Acceptance to publication24 days
CiteScore5.300
Journal Citation Indicator-
Impact Factor-
 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.